Darbepoetin alfa administered once every three weeks for the treatment of anemia in elderly patients with non-myeloid tumors receiving chemotherapy

作者：Esquerdo Gaspar; Domenech Mercedes; Lopez Pilar; Pedro Carme; Villadiego Kenny; Constenla Manuel; Sanchez Rovira Pedro; Gasquet Jose A; Rodriguez Cesar A^*

来源：Tumori, 2014, 100(2): 225-231.

• anemia
• darbepoetin alfa
• chemotherapy
• solid tumors
• lymphoproliferative malignancies
• transfusion

Aims and background. The present study aims to describe the hematological response to darbepoetin alfa (DA) under daily clinical practice conditions in anemic elderly patients with non-myeloid tumors receiving chemotherapy. %26lt;br%26gt;Methods and study design. This was a prospective, observational, multicenter study in elderly (%26gt;= 65 years) patients with non-myeloid cancer receiving DA (500 g every 3 weeks) for chemotherapy-induced anemia (hemoglobin [Hb] level %26lt;= 11.0 g/dL). %26lt;br%26gt;Results. A total of 102 anemic patients with solid tumors and 51 with hematological malignancies were included in 28 centers in Spain. Mean age (+/- SD) was 73.4 (+/- 5.8) years, and mean baseline Hb level was 10.0 (+/- 0.8) g/dL. DA was administered for a median of 8 weeks. Of the 115 subjects with a post-baseline Hb value, the percentage of patients who achieved a hematopoietic response (Hb increase %26gt;= g/dL or reaching %26gt;= 12 g/dL without transfusions in the previous 28 days) was 69.7% (95% CI 56.1% to 83.3%). Functional Assessment of Cancer Therapy-Fatigue subscale scores increased during the study (median change 1.0 [Q1-5.0, Q3 9.0], P = 0.04). One patient (0.7%) experienced a non-serious adverse reaction (cutaneous rash). %26lt;br%26gt;Conclusion. The study results suggest that DA is an effective and well-tolerated therapy for the treatment of chemotherapy-induced anemia in elderly patients.

• 出版日期2014-4